Fig. 2: Immunogenicity and protective efficacy of Ad26.ZEBOV, MVA-BN-Filo regimens in NHP.

Nonsurviving NHP are depicted by open circles. a EBOV GP-binding antibody concentrations (ELISA units [EU]/mL, log₁₀ transformed) by regimen as determined by Filovirus Animal Non-Clinical Group (FANG) EBOV GP ELISA (BBRC); group means are indicated; samples below the lower limit of detection (LOD) are plotted at a common value (dotted line). b EBOV neutralizing antibody titers (IC₅₀, log₁₀ transformed) as determined by pseudovirus neutralization assay (psVNA; Monogram); group means are indicated; dotted line is LOD. Three samples could not be analyzed due to sample volume limitations. c EBOV GP-reactive IFN-γ T cells (spot-forming units [SFU]/10⁶ cells, log₁₀ transformed) as enumerated by IFN-γ ELISpot (TBRI); group means are indicated; samples below LOD are plotted at a common value (dotted line). d Table shows vaccine dose, dose order, and dose interval, as well as the associated survival after challenge. Additional regimens tested, as well as an overview by regimen can be found in Supplementary Fig. 2 and Supplementary Table 1. Dose of Ad26.ZEBOV (green) and MVA-BN-Filo (blue) as well as dose interval (shades of red and pink). Yellow shading identifies regimens with 100% protection. ELISA enzyme-linked immunosorbent assay, IFN-γ ELISpot interferon-gamma enzyme-linked immunospot, EU ELISA units, IC₅₀ half-maximal inhibitory concentration, InfU infectious units, LOD limit of detection, psVNA pseudovirus neutralization assay, SFU spot-forming units, PBMC peripheral blood mononuclear cells, vp viral particles.